Theranexus : FY 2022 results contained no surprises, confirmation of development of Batten-1
>Financial visibility out to end-Q1 2024 at least - Theranexus reported an operating loss of € 6.3m in 2022 vs € 9.5m in 2021. The difference is attributable to an increase in operating income to € 1.2m in 2022 compared with € 0m in 2021. This is mainly due to grants for the Neurolead research platform. The group maintained a tight rein on operating costs: € 7.5m in 2022 vs € 9.5m in 2021. Theranexus had a net cash position of € 7.3m at 31 March 2023 (vs € 9m at ...Theranexus SA is a France-based company engaged in the healthcare industry. The Company is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The Company's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.